De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

1. Safety of crushed/chewed P2Y12 inhibitors in acute coronary syndromes - a meta-analysis of randomized controlled trials.Cardiovascular intervention and therapeutics · 2025
   Pooled it
2. Managing bleeds on anticoagulant therapy: a practical guide for clinicians.European heart journal. Acute cardiovascular care · 2026
   Review
3. A Clinician-Oriented Approach to Plaque Pathology in ACS: Implications for Personalized Cardiovascular Medicine-A Comprehensive Review.Journal of personalized medicine · 2026
   Review
4. Ticagrelor-based DAPT after CABG: in whom and for how long?Journal of thrombosis and thrombolysis · 2026
   Article
5. Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital.Journal of thrombosis and thrombolysis · 2025
   Article
6. Breaking boundaries: Ticagrelor monotherapy in high-risk patients.International journal of cardiology. Heart & vasculature · 2024
   Review
7. De-escalation of antithrombotic treatment after acute coronary syndrome, a new paradigm.Internal and emergency medicine · 2024
   Review
8. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis.Nature reviews. Cardiology · 2023
   Review
9. Management of Coronary Artery Disease in Older Adults: Recent Advances and Gaps in Evidence.Journal of clinical medicine · 2023
   Review
10. Advancements in Percutaneous Coronary Intervention Techniques: A Comprehensive Literature Review of Mixed Studies and Practice Guidelines.Cureus · 2023
    Review
11. Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease.Journal of thrombosis and thrombolysis · 2023
    Article
12. Editorial: Precision medicine for antithrombotic therapy in patients after percutaneous coronary interventions.Frontiers in cardiovascular medicine · 2023
    Article
13. Which future for aspirin in acute coronary syndromes treated with percutaneous coronary intervention? An overview on aspirin-free strategies.Archives of medical science : AMS · 2022
    Article
14. Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?Frontiers in cardiovascular medicine · 2022
    Review
15. EValuation of Acute and Early Phase P2Y12 Inhibitor DE-escalation After PerCutaneous Intervention (EVADE PCI).Kansas journal of medicine
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as